Thales welcomes changes to defence capability scheme
Thales Australia has welcomed what it calls the strengthening of Defence’s Australian Industry Capability Programme and the review of Australian Standard for Defence Contracting. The company, which spent $522 million with Australian firms in 2019, said there was strong evidence in support of the Government’s policy of requiring high levels of AIC in acquisition and sustainment. Analysis by AlphaBeta Advisors demonstrated that there is a substantial economic benefit from domestic defence spending. Thales Australia CEO Chris Jenkins said: “Increasing Australia’s industrial capability will build Australia’s self-reliance and the capability of the broader Australian advanced manufacturing sector, which is vital to delivering a capability advantage to the Australian Defence Force.”
Zoono wins United Airlines as a new customer
Anti-microbial solution manufacturer Zoono Group continues to win new customers for its surface sanitiser products, with United Airlines utilising its Zoono Microbe Shield products (pictured). United is spraying the product on more than 30 aircraft to seats, tray tables, armrests and other surfaces once a week and is expanding its use to its entire fleet. Zoono shield acts as an additional layer of protection that complements the airline’s daily electrostatic spraying before each flight departure.
Orthocell’s CelGro in positive clinical trial results
Bone regeneration technology company Orthocell’s CelGro product that helps bone repair has seen positive trial results published in the journal Tissue Engineering. The results showed the use of CelGro enhanced repair of bone defects in maxillofacial reconstructive surgery. and orthopedics. CelGro is approved in the European Union for dental and soft tissue reconstruction where it accelerates repair.
ABT receives tax offset payment
Sealed braking systems manufacturer Advanced Braking Technology has receives a $534,000 tax offset refund for its recent research and development expenditure. The company, whose products are used in demanding mining and defence uses, will use the funds as working capital to progress its strategy. Because of a strong financial position, ABT did not enter into a prepayment loan arrangement with financiers, which is popular among some companies. This means the full amount is now available to the company.
$6 million federal funding for three Covid-19 vaccine candidates
New funding through the Medical Research Future Fund was announced on Monday for three Australian R&D programs for Covid-19 vaccines. The University of Melbourne was awarded $3 million for two projects: development of a protein-based and an mRNA-based vaccine. The University of Sydney was awarded nearly $3 million for a Phase 1/1b clinical trial to test the safety and effectiveness of “a novel DNA-based” vaccine, delivered through a needle-free platform known as PharmaJet.
Picture: Zoono Microbe Shields
Subscribe to our free @AuManufacturing newsletter here.